Authors: Martha Powell, Future Science Group
Remember you can find us at booth #1.7d, or follow out Twitter updates @IDHubFSG
Pick of the Posters
1. Fluoroquinolone use and the risk of acute liver injury, by Nibell O from Lund University, conducted a registry based cohort study in a Swedish setting in order to assess whether oral fluoroquinolone use was associated with liver injury, discovering a more than six-fold risk of acute liver injury associated with oral fluoroquinolone use. The increased risk was most prominent during the first month after the start of treatment and seemed to decrease over time.
2. Neisseria gonorrhoeae antimicrobial resistance in Spain. Should we keep using azithromycin for empirical treatment? by Salmerón P form the Universitari Vall d’Hebron, carried out a muticenter study of nine hospitals in Spain, testing the susceptibility of gonorrhoea isolates obtained from patients. The authors concluded that gonorrhoea susceptibility to extended-spectrum cephalosporin remains high, however, the increased rate of azithromycin resistance (16%0 could threaten dual therapy, thus a surveillance program for the correct management of gonorrhoea should be developed.
Best of social media #ECCMID19
Margreet Vos Year in Infection control #ECCMID2019 “fake news and misinformation is a major disruptive force .. The answer is to collaborate in research”
— Diag Bacteriology (@10minus6cosm) April 15, 2019
TB, zebrafish, and #LTA4H. An engaging keynote talk from Prof Lalita Ramakrishnan, explaining the effect of LTA4H on inflammatory response to TB, genetic variations, and the current LTA4H stratified trial of corticosteroids in HIV uninfected #TBM in Vietnam @ThwaitesGuy @ECCMID
— Joseph Donovan (@drjosephdonovan) April 15, 2019
If you look at quality indicators for #AntimicrobialStewardship at a National level, the results are often disappointing, even when they can reduce mortality. #ECCMID2019 @BSACandJAC @UKCPAPIN pic.twitter.com/wTfP6eTcgN
— Philip Howard (@AntibioticLeeds) April 15, 2019